319 related articles for article (PubMed ID: 12920221)
21. Bcl-2 expression in human melanocytes and melanocytic tumors.
van den Oord JJ; Vandeghinste N; De Ley M; De Wolf-Peeters C
Am J Pathol; 1994 Aug; 145(2):294-300. PubMed ID: 8053490
[TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Chwirot BW; Kuźbicki Ł
Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
[TBL] [Abstract][Full Text] [Related]
23. Expression of the ets-1 proto-oncogene in human colorectal carcinoma.
Nakayama T; Ito M; Ohtsuru A; Naito S; Sekine I
Mod Pathol; 2001 May; 14(5):415-22. PubMed ID: 11353051
[TBL] [Abstract][Full Text] [Related]
24. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
25. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma.
Ding Y; Prieto VG; Zhang PS; Rosenthal S; Smith KJ; Skelton HG; Diwan AH
Cancer; 2006 Mar; 106(5):1123-9. PubMed ID: 16456815
[TBL] [Abstract][Full Text] [Related]
26. Nestin expression in cutaneous melanomas and melanocytic nevi.
Brychtova S; Fiuraskova M; Hlobilková A; Brychta T; Hirnak J
J Cutan Pathol; 2007 May; 34(5):370-5. PubMed ID: 17448190
[TBL] [Abstract][Full Text] [Related]
27. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi.
Park HS; Park CH; Choi BR; Lim MS; Heo SH; Kim CH; Kang SG; Whang KU; Cho MK
J Cutan Pathol; 2009 May; 36(5):511-6. PubMed ID: 19476517
[TBL] [Abstract][Full Text] [Related]
28. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
Isabel Zhu Y; Fitzpatrick JE
J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
[TBL] [Abstract][Full Text] [Related]
29. Tissue microarray analysis of ezrin, KBA.62, CD166, nestin, and p-Akt in melanoma versus banal and atypical nevi, and nonmelanocytic lesions.
Shanesmith RP; Smart C; Cassarino DS
Am J Dermatopathol; 2011 Oct; 33(7):663-8. PubMed ID: 21915031
[TBL] [Abstract][Full Text] [Related]
30. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
[TBL] [Abstract][Full Text] [Related]
32. Expression of the ets-1 proto-oncogene in human thyroid tumor.
Nakayama T; Ito M; Ohtsuru A; Naito S; Nakashima M; Sekine I
Mod Pathol; 1999 Jan; 12(1):61-8. PubMed ID: 9950164
[TBL] [Abstract][Full Text] [Related]
33. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
34. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration.
Rothhammer T; Poser I; Soncin F; Bataille F; Moser M; Bosserhoff AK
Cancer Res; 2005 Jan; 65(2):448-56. PubMed ID: 15695386
[TBL] [Abstract][Full Text] [Related]
35. Association of galectin-3 expression with melanoma progression and prognosis.
Brown ER; Doig T; Anderson N; Brenn T; Doherty V; Xu Y; Bartlett JM; Smyth JF; Melton DW
Eur J Cancer; 2012 Apr; 48(6):865-74. PubMed ID: 22071132
[TBL] [Abstract][Full Text] [Related]
36. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
37. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes.
Guerriere-Kovach PM; Hunt EL; Patterson JW; Glembocki DJ; English JC; Wick MR
Am J Clin Pathol; 2004 Jul; 122(1):70-7. PubMed ID: 15272532
[TBL] [Abstract][Full Text] [Related]
38. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
Einspahr JG; Thomas TL; Saboda K; Nickolof BJ; Warneke J; Curiel-Lewandrowski C; Ranger-Moore J; Duckett L; Bangert J; Fruehauf JP; Alberts DS
Cancer; 2007 Dec; 110(11):2519-27. PubMed ID: 17932890
[TBL] [Abstract][Full Text] [Related]
39. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.
Berger AJ; Kluger HM; Li N; Kielhorn E; Halaban R; Ronai Z; Rimm DL
Cancer Res; 2003 Dec; 63(23):8103-7. PubMed ID: 14678960
[TBL] [Abstract][Full Text] [Related]
40. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
